Akebia Therapeutics, Inc.
Compositions and methods for treating anemia

Last updated:

Abstract:

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Status:
Grant
Type:

Utility

Filling date:

31 Mar 2016

Issue date:

10 May 2022